Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

NCT03063086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: QVM149 150/50/80 μg o.d.
DRUG: QVM149 150/50/160 μg o.d.
DRUG: salmeterol/fluticasone FDC 50/500 μg b.i.d.

Sponsor

Novartis Pharmaceuticals